Oscient reiterated at market outperform by JMP

JMP Securities analyst Adam Cutler reiterated Oscient Pharmaceuticals Corp. at market outperform as the analyst continued to track weekly Factive and Testim (Auxilium Pharmaceuticals) prescription volumes using NDC Health data. For the week ended June 2, Factive total prescriptions were 4,683 (4,497 new), or 0.82% of weekly prescriptions for the quinolone class of antibiotics, compared with 6,004 total prescriptions (5,874 new) in the previous week, or 0.92% of weekly prescriptions. Through June 2, about 50,273 Factive prescriptions have been written, generating about $4.5 million in revenue. Total Testim scripts for the week ended June 2 were 5,496, compared with 5,912 for the previous week. Shares of the Waltham, Mass.-based biopharmaceutical company were down 2 cents, or 1.77%, at $1.11 on volume of 135,489 shares versus the three-month running average of 435,578 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.